Danna nan idan wannan shine sakin labaran ku!

Sabuwar Gwajin Cutar Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. (nan gaba koma zuwa "Lynk Pharmaceuticals '), wani m asibiti mataki kamfanin, ya sanar da kamfanin ya dosed farko haƙuri da LNK01001 a Phase II na asibiti fitina a batutuwa da rheumatoid amosanin gabbai (RA). LNK01001 mai hanawa ne da aka yi niyya don maganin cututtukan autoimmune.

Print Friendly, PDF & Email

An tsara nazarin asibiti don kimanta aminci da inganci na LNK01001 a cikin batutuwa masu matsakaici zuwa matsananciyar cututtuka na rheumatoid masu aiki waɗanda ke da mummunar amsawa tare da ko rashin haƙuri ga magungunan ƙwayoyin cuta na al'ada-gyaran magungunan antirheumatic (csDMARDs).

LNK01001 shine magani na farko da aka kirkira ta hanyar Lynk Pharmaceuticals, kuma shine zaɓin kinase inhibitor don maganin cututtukan autoimmune. A baya can, LNK01001 ya kammala karatun asibiti na Phase I a cikin batutuwa masu lafiya a lokacin rani na wannan shekara a Sin da Australia da Japan, wanda Lynk Pharmaceuticals da abokin tarayyar Amurka suka dauki nauyinsa, bi da bi. Sakamakon ya nuna cewa maganin yana da lafiya kuma yana da jurewa. Bugu da ƙari, LNK01001 ya amince da Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) don kimantawa na asibiti na sababbin alamun - ankylosing spondylitis (AS) da atopic dermatitis (AD).

Farfesa Xiaofeng Zeng shi ne babban jami'in binciken wannan binciken kuma darektan Sashen Nazarin Rheumatology da Immunology na Asibitin Kwalejin Kiwon Lafiyar Jama'a na Peking Union da Cibiyar Nazarin Kiwon Lafiya ta kasar Sin.

Print Friendly, PDF & Email

Game da marubucin

Linda Hohnholz, editan eTN

Linda Hohnholz tana rubuce-rubuce da gyara labarai tun farkon fara aikinta. Ta yi amfani da wannan sha'awar a wurare kamar su Hawaii Pacific University, Chaminade University, da Hawaii's Discovery Center, da yanzu TravelNewsGroup.

Leave a Comment